TABLE 1.

Clinicopathological characteristics and extent of expression of FasL and FasR in breast tumors

Patient	Tumor type	Gradea	Extent of expressionb
			FasL	FasR
1	Intraduct and infiltrating carcinoma	3	+++	+++
2	Intraduct and infiltrating carcinoma	3	+++	++++
3	Intraduct and infiltrating carcinoma	2	++++	++++
4	Intraduct and infiltrating carcinoma	3	+++	+++
5	Intraduct and infiltrating carcinoma	2	++++	++++
6	Intraduct and infiltrating carcinoma	2	++++	++++
7	Infiltrative ductal carcinoma	2	+++	+++
8	Infiltrative ductal carcinoma	1	+++	++++
9	Infiltrative ductal carcinoma	2	+++	+++
10	Ductal carcinoma in situ	NAc	+++	++++
11	Ductal carcinoma in situ	NA	++++	++++
12	Ductal carcinoma in situ	NA	+++	++++
13	Infiltrative mucinous carcinoma	Lowd	+++	+++
14	Mucinous adenocarcinoma	NDe	+++	++++
15	Infiltrative lobular carcinoma	2	+++	+++
16	Infiltrative lobular carcinoma	2	+++	+++
17	Tubular carcinoma	1	+++	+++

^aGraded by the Nottingham modification of Scarrf-Bloom-Richardson. 

^bExtent of expression was graded on the basis of the percentage of positive cells, as follows: +, 0 to 25%; ++, 25 to 50%; +++, 50 to 75%; ++++, 75 to 100%. 

^cNA, not applicable. 

^dGraded by conventional histopathological classification. 

^eND, not determined.